1. From the Imperial Cancer Research Fund Medical Oncology Unit, St Bartholomew's Hospital, London, Department of Haematology, Royal Bournemouth Hospital, Bournemouth, Department of Haematology, Taunton and Somerset Hospital, Taunton, and Department of Oncology, Queen Elizabeth Hospital, Birmingham, United Kingdom; and Pharmacokinetics Therapeutics and Clinical Development Oncology, Schering AG, Berlin, Germany.